Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
P R Health Sci J ; 27(3): 241-6, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18782970

RESUMEN

Atherosclerosis is the most frequent cause of ischemic heart disease and cerebrovascular disorders. The condition is the leading cause of death in Western societies. At the core of this condition is the atherosclerotic plaque. It is within the structure of this lesion that multiple biochemical and cellular processes interact influencing its vulnerability to rupture and as a result acute ischemic events. This article will discuss the pathophysiology behind the atherosclerotic plaque, particularly those elements that lead to its instability and the medical tools currently available to counteract it.


Asunto(s)
Aterosclerosis , Aterosclerosis/diagnóstico , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/etiología , Humanos
2.
Bol. Asoc. Méd. P. R ; 97(4): 248-256, Oct.-Dec. 2005.
Artículo en Inglés | LILACS | ID: lil-442764

RESUMEN

BACKGROUND: Heart transplantation is the procedure of choice for a selected group of patients with end stage heart disease. Gender related differences have been observed in the heart transplant field: less women than men are recipients of heart transplants, more risk of rejection in female recipients, and a perception toward reduced survival in women. We report our experience of heart transplantation in females in Puerto Rico. METHODS: We studied the data bank of 69 heart transplant recipients in the Puerto Rico Heart Transplant Program from June 1999 to June 2005. Gender related differences in the number of recipients: males or females, incidence of rejection, survival, and other outcomes were analyzed. RESULTS: 69 patients received an orthotopic heart transplant from June 1999 to June 2005, in a single center in Puerto Rico. The mean age of the patients was 47 (11-62) years. Fifty patients (72%) were men, and 19 patients (28%), were women. Survival in the female group at 3 months, 1, 2, 3, 4, and 5 years was 100%, 100%, 100%, 100%, 90%, and 90% respectively. The survival in the male group at 3 months, 1, 2, 3, 4 and 5 years was 97%, 97%, 97%, 94%, 86 and 79% respectively. There was an early, higher incidence of rejection in women during the first three months post transplant; 1.5 vs. 0.75, (P=0.04) episodes per patient in the female, and male group respectively. After the third month post transplant there was no significant difference in rejection incidence. The incidence of infectious episodes was significantly more frequent in female than in male recipients, 2.8 vs. 1 (P=0.02) per patient respectively. CONCLUSIONS: There were more male than female heart transplant recipients at a ratio of 3:1, without a significant gender difference in survival. The risk of rejection was higher in females in the early period post transplantation, but thereafter this risk showed no signinificant statistical difference. The incidence of infection was more frequent in female...


Asunto(s)
Humanos , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Trasplante de Corazón/estadística & datos numéricos , Factores de Edad , Complicaciones Posoperatorias/epidemiología , Incidencia , Puerto Rico , Estudios Retrospectivos , Rechazo de Injerto/epidemiología , Factores Sexuales , Análisis de Supervivencia , Factores de Tiempo , Trasplante de Corazón/mortalidad
3.
P R Health Sci J ; 13(2): 125-8, 1994 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7938398

RESUMEN

Twelve patients with ischemic heart disease had complete left and right catheterization before and after sublingual captopril. Hemodynamic measurements were ten (10) minutes apart and were monitored for thirty (30) minutes. The heart rate increased from 70 +/- 13 to 76 +/- 11 beats/minute (P = .04). There was no change in the arterial blood pressure, although the systemic vascular resistance decreased from 1500 +/- 400 to 1026 +/- 480 dynes-sec-cm-5 (P < .0001). The pulmonary artery pressure was increased 15 +/- 6 to 25 +/- 5mmHg (P = .005) and the pulmonary vascular resistance increased from 288 + 160 to 376 + 160 dynes-sec-cm-5 (P < .0001). The wedge pressure increased from 7 +/- 2 to 14 +/- 3 mmHg (P = .05). The cardiac output (CO) increased from 5.06 +/- 1.06 to 578 +/- 1.58 Lt/min. (P.05 =. The left ventricular end diastolic volume (LVEDV) increased from 128 +/- 40 to 145 +/- 37cc)P = .002), without change in the end systolic volume (ESV). The ejection fraction (EF) increased from 56 +/- 3 to 61 +/- 4% (P = .02). These pressure changes appeared at two (2) minutes and disappeared after thirty (30) minutes. The study shows that, sublingual captopril produces a transient elevation of the pulmonary artery pressure and resistance.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Presión Sanguínea/efectos de los fármacos , Isquemia Miocárdica/fisiopatología , Arteria Pulmonar/fisiopatología , Administración Sublingual , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Captopril/administración & dosificación , Captopril/farmacología , Cateterismo Cardíaco , Hemodinámica , Humanos , Persona de Mediana Edad , Resistencia Vascular/efectos de los fármacos
4.
Am J Hypertens ; 6(7 Pt 1): 570-8, 1993 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8397997

RESUMEN

Hypertension is a major risk factor for the development of heart failure. Despite significant progress in our knowledge of the physiopathology of heart failure, the cause for decompensation in patients with left ventricular hypertrophy (LVH) is still obscure. The angiotensin converting enzyme inhibitor enalaprilat has been found to improve electromechanical coupling of heart cells in animal models. To assess the effects of enalaprilat on ventricular electromechanical coupling in humans, we studied the His bundle electrograms and hemodynamics in 22 hypertensive patients with LVH. Patients received either 2.5 mg enalaprilat or saline placebo intravenously in a double-blind protocol. There were no significant changes in heart rate, and atrioventricular and His-Purkinje conduction times. Ventricular activity duration was reduced from 110 +/- 11 msec to 88 +/- 13 msec after enalaprilat administration (P < .01). Enalaprilat decreased peak-systolic and end-diastolic left ventricular pressures, and arterial and pulmonary pressures, as well as pulmonary and systemic vascular resistances. End-systolic wall stress decreased 18% (P < .01), ejection fraction increased 11% (P < .01), and end-diastolic pressure-volume ratio decreased 50% (P < .001) after enalaprilat administration. There were no significant changes in these parameters after saline infusion. It is concluded that enalaprilat reduces ventricular activation duration and improves ventricular performance in hypertensive patients with LVH. Data suggest that enalaprilat significantly improves excitation-contraction coupling in these patients.


Asunto(s)
Enalaprilato/farmacología , Hemodinámica/efectos de los fármacos , Hipertensión/fisiopatología , Función Ventricular Izquierda/efectos de los fármacos , Potenciales de Acción/efectos de los fármacos , Cateterismo Cardíaco , Método Doble Ciego , Electrocardiografía , Electrofisiología , Enalaprilato/uso terapéutico , Femenino , Sistema de Conducción Cardíaco/efectos de los fármacos , Insuficiencia Cardíaca/etiología , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Hipertrofia Ventricular Izquierda/complicaciones , Masculino , Persona de Mediana Edad , Contracción Miocárdica/efectos de los fármacos , Estudios Prospectivos
5.
P R Health Sci J ; 10(1): 15-8, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1876675

RESUMEN

Ten elderly patients each had a ventricular rate responsive pulse generator (Activitrax) placed in them to help correct severe conduction abnormalities; none had suspected ischemic heart disease. The pulse generator was programmed to a maximal pacing rate of 125 ppm, a medium activity threshold, and a rate response of 6. Six weeks after implantation of the pulse generator, the patients were evaluated before exercising and again when the pacing rate reached 125 ppm. The evaluation protocol included an M-mode echocardiogram from which the following measurements were taken: the left ventricular end-diastolic volume (EDV), the end-systolic volume (ESV), the ejection fraction (EF), and the peak systolic pressure/end-systolic volume (PSP/ESV). The numerical values were recorded, calculated, and compared statically with the following results: the EDV increased from 91 +/- 10 to 125 +/- 20 cc (p less than .05); the ESV decreased from 64 +/- 10 to 24 +/- 6 cc (p less than .005); the EF increased from 41 +/- 5 to 61 +/- 10% (p less than .05); and the PSP/ESV ratio increased from 1.70 +/- 1 to 4.10 +/- 2 mm Hg/cc (p = 10). Also, during the maximal pacing rate, the septum of all patients showed paradoxical septal motion. All patients in our study have been asymptomatic and have shown an increase in their exercise capacity. We conclude that during exercise the left ventricular function ins influenced more by heart rate than by AV synchrony, as indicated by an elevated EDV in most patients.


Asunto(s)
Arritmias Cardíacas/terapia , Técnicas Biosensibles , Frecuencia Cardíaca/fisiología , Marcapaso Artificial , Función Ventricular , Anciano , Presión Sanguínea , Gasto Cardíaco , Ecocardiografía , Electrocardiografía , Humanos , Volumen Sistólico , Función Ventricular Izquierda
7.
P R Health Sci J ; 6(1): 17-21, 1987 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-3112859

RESUMEN

Sixteen patients with secundum atrial defect were catheterized giving emphasis to the analysis of the left ventricle at end systole and mid-ejection. The mean ejection fraction of the group was subnormal 57 + 8% when compared with 30 normal patients (71 + 109) P less than .005. Eight patients showed elevated end-diastolic volumes (156 + 10cc) when compared to our normal group (95% + 10cc) P less than .005. A total of 32 hypokinetic and 35 tardokinetic areas were found. Eight patients were restudied after nitroglycerin (0.4 mg sublingually) with an improvement in the ejection fraction from 54% to 70% (P less than .005) and normalization of most of the hypokinetic areas. No correlation was found between total ejection fraction or total systolic wall motion and the shunt size. Probably these left ventricular wall motion abnormalities are primary and not due to the shunt size.


Asunto(s)
Defectos del Tabique Interatrial/fisiopatología , Nitroglicerina/farmacología , Volumen Sistólico/efectos de los fármacos , Adolescente , Adulto , Cateterismo Cardíaco , Niño , Femenino , Atrios Cardíacos/fisiopatología , Humanos , Masculino , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA